Jose R Castillo-Mancilla1, Susan E Cohn2, Supriya Krishnan3, Michelle Cespedes4, Michelle Floris-Moore5, Gail Schulte6, Gregory Pavlov7, Donna Mildvan8, Kimberly Y Smith9. 1. University of Colorado-AMC, Aurora, Colorado. 2. Northwestern University, Feinberg School of Medicine, Chicago, Illinois. 3. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts. 4. New York University School of Medicine, New York, New York. 5. University of North Carolina School of Medicine, Chapel Hill, North Carolina. 6. Social and Scientific Systems, Silver Spring, Maryland. 7. Frontier Science & Technology Research Foundation, Inc, Amherst, New York. 8. Beth Israel Medical Center, New York, New York. 9. Rush University Medical Center, Chicago, Illinois.
Abstract
BACKGROUND AND OBJECTIVE: The reasons for minority underrepresentation in HIV/AIDS clinical trials remain unclear. We aimed to evaluate the knowledge, experience, and factors that influence minority participation in HIV/AIDS studies in the United States. METHODS: An anonymous, bilingual, self-administered survey on study participation was given to HIV-infected adults attending AIDS Clinical Trials Group-affiliated clinics in the United States and Puerto Rico. Chi-square tests were used to evaluate differences by race, first language, and level of education. Logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) for factors associated with being talked to about participation in a study. RESULTS: We analyzed 2,175 complete surveys (221 in Spanish). Among respondents, 31% were White, 40% were Black/African American (AA), and 21% were Hispanic. The overall rate of previous participation in any HIV/AIDS study was 48%. Hispanics were less likely to know about studies compared to Whites and AAs (67% vs 74% and 76%, respectively; P < .001). Compared to Whites, AAs and Hispanics were less likely to have been talked to about participating in a study (76% vs 67% and 67%, respectively; P < .001). The OR for being talked to about participating in a study was 0.65 (95% CI, 0.52-0.81) for AAs and 0.65 (95% CI, 0.49-0.85) for Hispanics, compared to Whites. AAs and Hispanics were more likely to state that studies were not friendly to their race (17% and 10% vs 4%; P < .001). CONCLUSIONS: Minorities continue to face barriers for HIV/AIDS trial participation, even when clinical research is available. Enrollment strategies should better target minorities to improve recruitment in HIV/AIDS research.
BACKGROUND AND OBJECTIVE: The reasons for minority underrepresentation in HIV/AIDS clinical trials remain unclear. We aimed to evaluate the knowledge, experience, and factors that influence minority participation in HIV/AIDS studies in the United States. METHODS: An anonymous, bilingual, self-administered survey on study participation was given to HIV-infected adults attending AIDS Clinical Trials Group-affiliated clinics in the United States and Puerto Rico. Chi-square tests were used to evaluate differences by race, first language, and level of education. Logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) for factors associated with being talked to about participation in a study. RESULTS: We analyzed 2,175 complete surveys (221 in Spanish). Among respondents, 31% were White, 40% were Black/African American (AA), and 21% were Hispanic. The overall rate of previous participation in any HIV/AIDS study was 48%. Hispanics were less likely to know about studies compared to Whites and AAs (67% vs 74% and 76%, respectively; P < .001). Compared to Whites, AAs and Hispanics were less likely to have been talked to about participating in a study (76% vs 67% and 67%, respectively; P < .001). The OR for being talked to about participating in a study was 0.65 (95% CI, 0.52-0.81) for AAs and 0.65 (95% CI, 0.49-0.85) for Hispanics, compared to Whites. AAs and Hispanics were more likely to state that studies were not friendly to their race (17% and 10% vs 4%; P < .001). CONCLUSIONS: Minorities continue to face barriers for HIV/AIDS trial participation, even when clinical research is available. Enrollment strategies should better target minorities to improve recruitment in HIV/AIDS research.
Entities:
Keywords:
AIDS; HIV; clinical trials; minority; research participation; underrepresented
Authors: Frinny R Polanco; Dinora C Dominguez; Christine Grady; Pamela Stoll; Catalina Ramos; Joann M Mican; Robert Miranda-Acevedo; Marcela Morgan; Jeasmine Aizvera; Lori Purdie; Deloris Koziol; Migdalia V Rivera-Goba Journal: J Assoc Nurses AIDS Care Date: 2011-02-01 Impact factor: 1.354
Authors: Marya Viorst Gwadz; Pablo Colon; Amanda S Ritchie; Noelle R Leonard; Charles M Cleland; Marion Riedel; DeShannon Bowens; Angela D Banfield; Patricia Chang; Robert Quiles; Donna Mildvan Journal: Curr HIV/AIDS Rep Date: 2010-11 Impact factor: 5.071
Authors: Allen L Gifford; William E Cunningham; Kevin C Heslin; Ron M Andersen; Terry Nakazono; Dale K Lieu; Martin F Shapiro; Samuel A Bozzette Journal: N Engl J Med Date: 2002-05-02 Impact factor: 91.245
Authors: S Sengupta; R P Strauss; R DeVellis; S C Quinn; B DeVellis; W B Ware Journal: J Acquir Immune Defic Syndr Date: 2000-07-01 Impact factor: 3.731
Authors: Marya Gwadz; Charles M Cleland; Mindy Belkin; Amanda Ritchie; Noelle Leonard; Marion Riedel; Angela Banfield; Pablo Colon; Vanessa Elharrar; Jonathan Kagan; Donna Mildvan Journal: AIDS Behav Date: 2014-12
Authors: Amanda Ritchie; Marya Viorst Gwadz; David Perlman; Rebecca De Guzman; Noelle R Leonard; Charles M Cleland Journal: J AIDS Clin Res Date: 2016-12-29
Authors: Suzanne Day; Allison Mathews; Meredith Blumberg; Thi Vu; Hailey Mason; Stuart Rennie; JoAnne D Kuruc; Cynthia L Gay; David M Margolis; Joseph D Tucker Journal: AIDS Date: 2020-07-01 Impact factor: 4.177
Authors: Gregory K Robbins; Susan E Cohn; Linda J Harrison; Laura Smeaton; Laura Moran; David Rusin; Marjorie Dehlinger; Theresa Flynn; Sara Lammert; Albert W Wu; Steven A Safren; Nancy R Reynolds Journal: HIV Clin Trials Date: 2016-07